Multiple Sclerosis Risk After Optic Neuritis: Title and subTitle BreakFinal Optic Neuritis Treatment Trial Follow-up FREE

Optic neuritis, an acute inflammatory disorder of the optic nerve, typically presents with sudden monocular visual loss and eye pain in young adults, more commonly in women. It is a common initial manifestation of multiple sclerosis (MS).¹ When optic neuritis occurs, brain magnetic resonance imaging (MRI) often demonstrates white-matter T2-weighted signal abnormalities consistent with demyelination (hereinafter referred to as lesions).² The Optic Neuritis Treatment Trial (ONTT) was a randomized trial that evaluated the use of corticosteroids in the treatment of acute optic neuritis. The ONTT showed that a 3-day course of methylprednisolone sodium succinate given intravenously in a dose of 250 mg every 6 hours followed by 2 weeks of oral prednisone in a dose of 1 mg/kg/d accelerated visual recovery but did not improve the eventual visual outcome.^{3 - 4} Treatment with oral prednisone alone in a dose of 1 mg/kg/d for 2 weeks also did not improve visual outcome and was associated with an increased rate of optic neuritis recurrences. An unexpected finding was that those who received intravenous corticosteroids followed by oral corticosteroids had a temporarily reduced risk of development of a second demyelinating event consistent with MS during the first 2 years compared with subjects who received oral corticosteroids alone or placebo.⁵

The ONTT cohort has been followed up for 15 years. This report describes the results of the final examination, including the risk of developing MS after optic neuritis and factors predictive of high and low risk.

Written informed consent for study participation was obtained from all patients on ONTT entry and again before each follow-up phase. Institutional review board oversight remained in effect for each participating clinical center. Methods and earlier results have been described previously.^{3 ,5 - 9} Pertinent details are summarized herein.

Patients with acute unilateral optic neuritis were enrolled between July 1, 1988, and June 30, 1991, and randomly assigned to 1 of 2 corticosteroid regimens or placebo. Standardized unenhanced MRI of the brain (5-mm slices with a 2.5-mm gap using primarily 1.5-T scanners) was performed at enrollment, and the number of white matter lesions at least 3 mm in diameter was determined with standardized grading by a central reading center.² After the first year of follow-up, examinations were performed annually through 1997 and then again in 2001 through 2002 (hereinafter referred to as the 10-year examination). Telephone contact was maintained with consenting patients until 2006, when patients returned for reexamination. The 2006 examinations (hereinafter referred to as the 15-year examination) were performed at 1 of the 13 remaining ONTT centers when possible (2 original centers were no longer participating). Similar to previous examinations, this examination included a neurologic and an ophthalmologic assessment.

Diagnostic criteria for MS were based on the Poser clinical criteria for clinically definite MS¹⁰ and consistent with the clinical criteria for MS that are part of the McDonald criteria diagnostic scheme.¹¹ Optic neuritis at study entry was considered 1 documented event. To meet MS diagnostic criteria, a patient had to have a clinical examination documenting a second new neurologic deficit attributable to central nervous system demyelination, consistent with neurologic symptoms lasting at least 24 hours and separated by at least 4 weeks from the initial optic neuritis event. Recurrent optic neuritis episodes in either eye were not considered in the diagnostic criteria for MS. Neurologic disability was assessed by a neurologist using the Kurtzke Functional Systems Scale and Expanded Disability Status Scale (EDSS).¹² The EDSS score was estimated from telephone interviews with 2 patients with MS who did not undergo a 15-year examination. Four patients who died of MS-related causes were assigned an EDSS score of 10.0.

The MS diagnosis date was the onset date of a second demyelinating event. For patients who did not develop MS, the last contact date (the most recent neurologic examination or, for those with no 15-year examination, a telephone assessment during which the patient reported no history consistent with development of MS) was used as the censoring date for analyses. We used life-table methods to compute the cumulative probability of developing MS within the intervals defined by the study's examination schedule (annual examinations during the first 5 years, the period after the 5- and through the 10-year examinations, and the period after the 10- and through the 15-year examinations). Cox proportional hazards modeling was used to assess baseline factors as potential predictors of MS separately for patients with and without lesions on baseline MRI. Hazard ratios of greater than 2.0, with 95% confidence intervals (CIs) not including 1.0, were considered suggestive of a meaningful association. The association of disability and number of lesions on baseline MRI was evaluated with the Spearman rank correlation test. Reported P values are 2-tailed. We used SAS statistical software (version 9.1; SAS Institute Inc, Cary, North Carolina) for analyses.

The study enrolled 389 patients with acute unilateral optic neuritis who were not diagnosed with probable or definite MS. Mean (SD) age at study entry was 32 (7) years; 77% were female and 85% were white.

The aggregate cumulative probability of developing MS by the 15-year examination was 50% (95% CI, 44%-56%) and was strongly related to the presence of lesions on the baseline brain MRI. That probability was 25% (95% CI, 18%-32%) for patients with no lesions and 72% (95% CI, 63%-81%) for patients with 1 or more lesions (Table 1 and Figure). Four deaths attributable to MS occurred. Three of these patients had undergone baseline MRI, at which 1 had no lesions, 1 had 2 lesions, and 1 had more than 10 lesions. There was no appreciable difference in the risk of developing MS among the 3 original ONTT treatment groups (15-year cumulative probability [95% CI] of MS, 45% [34%-56%] in the intravenous corticosteroid group, 51% [40%-62%] in the oral corticosteroid group, and 53% [42%-64%] in the placebo group).

The risk of developing MS was highest in the first 5 years and then decreased, although the risk remained substantial throughout the 15 years of follow-up in patients who had lesions on baseline brain MRI. Among patients without MS at the 10-year examination, the probability of developing MS by the 15-year examination was 32% when 1 or more baseline lesions were present vs 2% when there were no baseline lesions (Table 2).

For the analysis of MS development, data were considered to be complete for 300 of the 389 patients (77%) (157 with MS, 136 without MS who completed the 15-year examination, and 7 who did not complete the examination but for whom telephone contact verified that no neurologic symptoms consistent with MS had occurred since the last examination). Among the remaining 89 patients, the median follow-up time was 5.2 years (interquartile range, 2.1-7.0 years). Twelve patients died of causes unrelated to MS. Four patients reported receiving immunomodulatory drugs, although they did not meet the study's diagnostic criteria for MS.

The predictive value of baseline factors for the development of MS varied depending on the presence or the absence of lesions on baseline brain MRI. When 1 or more lesions were present at study entry, no demographic or clinical characteristics were predictive of MS development (Table 3). In contrast, among patients without lesions, the risk of MS was higher for women when there was a history of a viral syndrome preceding the optic neuritis onset and when the optic disc appeared to be normal at the time of visual loss (retrobulbar neuritis).

Multiple sclerosis developed in 1 of 24 men (4%) with no lesions on the baseline brain MRI and optic disc swelling at onset of visual loss, compared with 9 of 57 women (16%) with these characteristics. Among patients with monofocal optic neuritis at study entry (no lesions on baseline brain MRI, no prior optic neuritis in the contralateral eye, and no prior neurologic symptoms or signs), MS did not develop in any patient when baseline ophthalmoscopy showed severe optic disc swelling (n = 21), disc or peripapillary hemorrhages (n = 16), or retinal macular exudates (n = 8), when pain was absent (n = 18), or when vision was reduced to no light perception (n = 6).

An EDSS score was available for 113 patients with MS who completed the 15-year examination, 4 patients who died of the effects of MS, and 2 patients for whom the EDSS score was estimated from a telephone interview. Among these patients, 66% had an EDSS score of less than 3 and 13% had an EDSS score of at least 6. Degree of disability was not related to the number of brain lesions on the baseline MRI scan (Spearman correlation coefficient ±95% CI, r = 0.07 ± 0.19) (Table 4). Among the 38 patients with MS for whom a current EDSS score was unavailable, median follow-up was 6 years (interquartile range, 5-8 years). At the last neurologic examination after MS diagnosis, the EDSS score for these patients was less than 3 in 25, 3 to less than 6 in 4, and at least 6 in 3 (6 had not had an EDSS assessment after being diagnosed as having MS). Among the 113 patients completing the examination, 67 (59%) reported current use of disease-modifying therapy, 26 (23%) reported use in the past but no current use, and 20 (18%) reported no current or past use. The use of disease-modifying therapy among subjects with and without lesions on the baseline brain MRI was similar.

A relationship between optic neuritis and MS has been well recognized for many years. In this longitudinal study, the 15-year risk of developing MS was 50% based on clinical criteria alone. The risk was strongly related to MRI evidence of prior demyelination in the white matter of the brain at the time of optic neuritis onset (25% when no lesions were present and 72% when lesions were present). When at least 1 lesion was present, the risk was fairly consistent throughout the 15 years and did not substantially increase when additional lesions were present. For patients without brain lesions at onset, the risk of MS was greatest in the first 5 years, and if MS did not develop in the first 10 years, the risk during the period between the 10- and 15-year examinations approached 0; only 1 patient without lesions at study entry developed MS during the period between the 10- and 15-year examinations.

Regardless of whether lesions were present on brain MRI at the time of the optic neuritis episode, neurologic disability was mild in most patients who developed MS. However, because treatment of MS was not controlled in the study and most patients who developed MS were treated with disease-modifying therapies, we could not determine the degree of disability that occurs without treatment.

There was a clear distinction in the risk profile between patients with and without evidence of prior demyelination on brain MRI (≥ 1 lesion). Patients with abnormal brain MRI findings already have morphologic evidence of disseminated disease and could be considered to have MS at the time of the optic neuritis episode. Thus, it is not surprising that we did not identify any factors modifying the risk of MS in this group. In contrast, among patients with normal brain MRI findings, 2 subsets may exist, one destined to have MS and the other with a non–MS-related process of unknown cause.

Among patients without lesions on baseline brain MRI, the risk of MS was 3 times higher in women, consistent with the well-described sex predilection of MS. In addition, MS was more than twice as likely to develop when optic neuritis affected the retrobulbar part of the optic nerve rather than the anterior optic nerve, consistent with the common belief that retrobulbar neuritis is the typical form of optic neuritis in MS. Men with anterior optic neuritis had a lower risk of MS, whereas both sexes had a low risk when atypical features of the optic neuritis were present, namely, no light perception in the affected eye, absence of periocular pain, and ophthalmoscopic findings of severe optic disc swelling, peripapillary hemorrhages, or retinal exudates.

Our finding of a 50% 15-year risk of MS after optic neuritis is similar to several previous reports^{13 - 15} and lower than others^{16 - 18} ; however, all previous series had smaller sample sizes. Differences in risk estimates across studies also may be attributable to differences in patient inclusion criteria, retention rates, and diagnostic criteria for MS. The most similar study included 71 patients who presented with an acute demyelinating syndrome, 36 (51%) of whom had optic neuritis.¹⁶ During a mean follow-up of 14.1 years, clinically definite MS developed in 4 of 21 patients (19%) with normal brain MRI findings at study entry and in 44 of 50 patients (88%) with an abnormal finding. That study found, as we did, that, once there was at least 1 lesion on brain MRI, more lesions did not appreciably affect long-term risk of MS.

Our finding of a low frequency of substantial disability among patients who developed MS is similar to some previous studies^{13 ,19} but not others.^{16 ,20} Unlike Brex et al,¹⁶ we found that the number of lesions on baseline brain MRI was not associated with the degree of disability. In our study, moderate or severe disability was present in 39% of patients with no baseline lesions and in 31% of patients with 1 or more lesions. Because the reported use of disease-modifying therapy among subjects with and without brain lesions on MRI scans was similar, it is unlikely that the difference in severe disability between these 2 groups can be attributed to a higher rate of treatment among those with lesions. Previous studies have reported that the MS course is more benign when the initial event is optic neuritis rather than a brainstem or spinal cord syndrome.^{21 - 22} Thus, differences in results between our study and that of Brex et al¹⁶ may be related to the fact that patients with optic neuritis constituted only 50% of their study cohort.

Eligibility criteria were sufficiently broad that our results should be applicable to most patients presenting with optic neuritis as a first demyelinating event. Having incomplete data for 23% of the cohort is unlikely to be a source of appreciable bias because most of these patients completed at least 5 years of follow-up. Because few patients without MS in our study were treated prophylactically with immunomodulatory drugs, our risk estimate is not biased by use of therapies that have become available since the study began. One important factor to consider in interpreting our results is the technologic MRI advances that have occurred since the initiation of our study in 1988. Current imaging techniques are more sensitive in the detection of demyelination and might distinguish the risk of MS according to the presence or absence of MRI abnormalities to an even greater extent than we found. Current diagnostic criteria for MS permit dissemination of demyelinative lesions in time to be documented with MRI in lieu of a second clinical event.¹¹

Our results are important to clinicians in several respects. They reaffirm the prognostic value of a brain MRI at the time of a first episode of optic neuritis because presence of even a single lesion more than doubles the future risk of MS. Patients with abnormal brain MRI findings at the time of optic neuritis continue to be at substantial risk for the development of MS, even if they have not developed MS within 10 years after onset of optic neuritis. The very low risk of MS when atypical features of optic neuritis are present highlights the importance of an ophthalmologic examination to identify these features, particularly for patients with normal brain MRI findings. With normal brain MRI findings, MS is extremely unlikely to develop more than 10 years after the initial optic neuritis episode. Although our follow-up is only 15 years, it seems reasonable to conclude that the future risk for these patients will remain exceedingly low. Among patients who develop MS, most will follow a relatively benign neurologic course for many years.

The initiation of prophylactic treatment for MS at the time of an optic neuritis episode or of another first demyelinating event is controversial.^{23 - 24} Although our study cannot define which patients may benefit from prophylactic treatment, the results certainly justify withholding treatment in patients with a typical first episode of acute monosymptomatic optic neuritis who have a normal brain MRI finding because many may never develop MS. For patients with an abnormal brain MRI finding at the time of a first attack of optic neuritis, one must balance their risk of developing MS with the potential adverse effects and cost of disease-modifying agents. Treatment may be appropriate, but that decision must be made on an individual basis for each patient, with consideration given to the results of additional ancillary testing.

Correspondence: Robin L. Gal, MSPH, Jaeb Center for Health Research, 15310 Amberly Dr, Ste 350, Tampa, FL 33647 (lons@jaeb.org).

Accepted for Publication: January 18, 2008.

Author Contributions: Dr Beck had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Beck, Brodsky, Gal, Kaufman, Miller, and Smith. Acquisition of data: Bhatti, Brodsky, Buckley, Cornblath, Eggenberger, Gal, Hamilton, Hutton, Irani, Kaufman, Keltner, Kupersmith, Massey, Miller, Nazarian, Orengo-Nania, Savino, Shults, Smith, and Trobe. Analysis and interpretation of data: Beck, Bhatti, Dontchev, Greer, Kollman, Miller, Smith, and Wall. Drafting of the manuscript: Beck, Brodsky, Dontchev, Gal, and Smith. Critical revision of the manuscript for important intellectual content: Beck, Bhatti, Brodsky, Buckley, Cornblath, Eggenberger, Gal, Greer, Hamilton, Hutton, Irani, Kaufman, Keltner, Kollman, Kupersmith, Massey, Miller, Nazarian, Orengo-Nania, Savino, Shults, Smith, Trobe, and Wall. Statistical analysis: Beck, Dontchev, and Kollman. Obtained funding: Beck and Gal. Administrative, technical, and material support: Bhatti, Brodsky, Cornblath, Eggenberger, Gal, Hamilton, Kaufman, Keltner, Kupersmith, Miller, Savino, Shults, and Trobe. Study supervision: Kollman, Miller, and Smith.

Financial Disclosure: Dr Smith is an employee of Genentech, Inc.

Funding/Support: This study was supported by a cooperative agreement EY09435 from the National Eye Institute, National Institutes of Health.